IBM vs Johnson & Johnson: Revenue, Profit and Business Model
IBM reported $67.5B of revenue in FY2025 and $10.6B of net income. Johnson & Johnson reported $94.2B of revenue in FY2025 and $26.8B of net income.
Latest financial snapshot
IBM
- Latest revenue
- $67.5B (FY2025)
- Net income
- $10.6B
- Net margin
- 15.7%
- Revenue growth
- -1.9% a year, FY2016–FY2025
Johnson & Johnson
- Latest revenue
- $94.2B (FY2025)
- Net income
- $26.8B
- Net margin
- 28.5%
- Revenue growth
- +3.0% a year, FY2016–FY2025
Financial summary
IBM
IBM's reported revenue fell from about $80 billion in 2016-2018 to $57.4 billion in 2021, mostly because the Kyndryl spin-off and earlier divestitures removed low-margin services. Since then the slimmer company has grown each year: $60.5 billion in 2022, $61.9 billion in 2023, $62.8 billion in 2024, and $67.5 billion in 2025 (up 7.6%). FY2025 net income from continuing operations was $10.6 billion and free cash flow was $14.7 billion. In Q2 2026, revenue rose 1% to $17.16 billion: software grew 5% to $7.76 billion, consulting was flat at $5.33 billion, and infrastructure fell 7% to $3.84 billion as IBM Z sales lapped the z17 launch. Some large software deals slipped out of the quarter, so IBM cut its 2026 constant-currency revenue growth forecast to 4-5% while keeping its target of about $1 billion more free cash flow than in 2025.
Johnson & Johnson
J&J's sales grew from $85.2 billion in 2023 to $88.8 billion in 2024 and $94.2 billion in 2025, while FY2025 net earnings reached $26.8 billion. Q2 2026 sales were $25.31 billion (Innovative Medicine $16.38 billion, MedTech $8.93 billion), net earnings were $5.53 billion, adjusted EPS was $2.90, and first-half free cash flow was about $8.7 billion. Management guides 2026 sales of $100.8 to $101.4 billion and adjusted EPS of $11.60 to $11.75. The company has raised its dividend for more than 60 consecutive years, and its market value was roughly $644 billion in mid-September 2026.
Revenue and profit by year
IBM
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | $67.5B | $10.6B | 15.7% | +7.6% | Source |
| FY2024 | $62.8B | $6B | 9.6% | +1.4% | Source |
| FY2023 | $61.9B | $7.5B | 12.1% | +2.2% | Source |
| FY2022 | $60.5B | $1.6B | 2.7% | +5.5% | Source |
| FY2021 | $57.4B | $5.7B | 10.0% | +3.9% | Source |
| FY2020 | $55.2B | $5.6B | 10.1% | -4.4% | Source |
| FY2019 | $57.7B | $9.4B | 16.3% | -27.5% | Source |
| FY2018 | $79.6B | $8.7B | 11.0% | +0.6% | Source |
| FY2017 | $79.1B | $5.8B | 7.3% | -1.0% | Source |
| FY2016 | $79.9B | $11.9B | 14.9% | — | Source |
Johnson & Johnson
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | $94.2B | $26.8B | 28.5% | +6.0% | Source |
| FY2024 | $88.8B | $14.1B | 15.8% | +4.3% | Source |
| FY2023 | $85.2B | $35.2B | 41.3% | +6.5% | Source |
| FY2022 | $80B | $17.9B | 22.4% | +1.6% | Source |
| FY2021 | $78.7B | $20.9B | 26.5% | -4.7% | Source |
| FY2020 | $82.6B | $14.7B | 17.8% | +0.6% | Source |
| FY2019 | $82.1B | $15.1B | 18.4% | +0.6% | Source |
| FY2018 | $81.6B | $15.3B | 18.8% | +6.7% | Source |
| FY2017 | $76.5B | $1.3B | 1.7% | +6.3% | Source |
| FY2016 | $71.9B | $16.5B | 23.0% | — | Source |
Where the revenue comes from
IBM
- Software~44%
Red Hat, automation, data and AI, transaction processing, security, and related software services.
- Consulting~31%
Technology consulting, business transformation, hybrid cloud implementation, and AI-enabled workflows.
- Infrastructure~23%
IBM Z, distributed infrastructure, storage, infrastructure software, maintenance, and related services.
- Financing~1%
Client financing and used equipment sales supporting enterprise technology deployments.
Johnson & Johnson
- Innovative Medicine~64%
Innovative Medicine generated $60.401 billion in FY2025 sales across oncology, immunology, neuroscience, pulmonary hypertension, infectious disease, and cardiovascular/metabolism.
- MedTech~36%
MedTech generated $33.792 billion in FY2025 sales across surgery, orthopaedics, cardiovascular, and vision products.
Business model and strategy
IBM
How it makes money
IBM makes money from four segments. Software ($29.96 billion in FY2025, about 44% of revenue) includes Red Hat Enterprise Linux and OpenShift, HashiCorp Terraform and Vault, Confluent data streaming (from March 2026), watsonx AI, automation, security, and mainframe transaction-processing software, sold mostly as subscriptions and recurring licenses.
Growth strategy
IBM does not try to beat AWS, Microsoft Azure, or Google Cloud at selling public cloud capacity. It sells the software layer that runs across all of them and across on-premises data centers.
Competitive advantage
IBM's main advantage is how deeply it is built into the core systems of large regulated organizations. Banks, card networks, insurers, and governments run high-volume transaction processing on IBM Z, and moving those workloads is slow, risky, and expensive.
Johnson & Johnson
How it makes money
J&J makes money in two ways. Innovative Medicine (about 64% of FY2025 sales, $60.4 billion) sells patented prescription medicines to wholesalers, specialty pharmacies, hospitals, and governments; key products include DARZALEX for multiple myeloma, TREMFYA and STELARA in immunology, ERLEADA in prostate cancer, CARVYKTI cell therapy, and CAPLYTA, added through the 2025 Intra-Cellular Therapies deal.
Growth strategy
J&J is narrowing its portfolio toward higher-growth areas. It spun off consumer health as Kenvue in 2023, announced in October 2025 that it will separate its orthopaedics business as DePuy Synthes, and used acquisitions to refill its pipeline: Abiomed ($16.6 billion, 2022), Shockwave Medical ($13.1 billion, 2024), and Intra-Cellular Therapies ($14.6 billion, 2025).
Competitive advantage
J&J's edge is breadth plus balance-sheet strength. It runs one of the largest pharmaceutical R&D budgets in the industry, holds a AAA credit rating from S&P (one of only two US companies with that rating, alongside Microsoft), and sells into hospitals across pharmaceuticals and devices at the same time.
Questions about IBM vs Johnson & Johnson
Which company has higher revenue — International Business Machines Corporation or Johnson & Johnson?
International Business Machines Corporation reported $67.5B (FY2025), while Johnson & Johnson reported $94.2B (FY2025). By last reported revenue, Johnson & Johnson is the larger business, with International Business Machines Corporation reporting a smaller revenue base.
What is the market cap of International Business Machines Corporation vs Johnson & Johnson?
International Business Machines Corporation's market capitalisation stands at $216.3B, while Johnson & Johnson's is $643.9B. Johnson & Johnson carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to International Business Machines Corporation.
Which is more financially efficient — International Business Machines Corporation or Johnson & Johnson?
International Business Machines Corporation generates $256k / employee in revenue per employee, while Johnson & Johnson generates $669k / employee. Johnson & Johnson shows higher revenue efficiency per headcount, though this reflects business model differences — capital-light software companies routinely outperform labour-intensive manufacturers on this metric.
How do International Business Machines Corporation and Johnson & Johnson make money?
International Business Machines Corporation and Johnson & Johnson generate revenue in fundamentally different ways. International Business Machines Corporation: IBM makes money from four segments. Johnson & Johnson: J&J makes money in two ways.
Which company is valued higher relative to revenue — International Business Machines Corporation or Johnson & Johnson?
On a price-to-sales (P/S) basis, International Business Machines Corporation trades at 3.2x P/S and Johnson & Johnson at 6.8x P/S. Johnson & Johnson commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to International Business Machines Corporation. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.
Is International Business Machines Corporation bigger than Johnson & Johnson?
By last reported revenue, Johnson & Johnson ($94.2B (FY2025)) is the larger company compared to International Business Machines Corporation ($67.5B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the IBM vs Johnson & Johnson overview